NeuBase Therapeutics, Inc. - FORM 10-K - EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - December 15, 2017

Attached files

file filename
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex32-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - NeuBase Therapeutics, Inc.ex23.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - NeuBase Therapeutics, Inc.ex21.htm
EX-10.11(C) - FORM OF RESTRICTED STOCK AGREEMENT - NeuBase Therapeutics, Inc.ex10-11c.htm
EX-10.11(B) - FORM OF STOCK OPTION AGREEMENT - NeuBase Therapeutics, Inc.ex10-11b.htm
10-K - ANNUAL REPORT - NeuBase Therapeutics, Inc.ohrp-10k_093017.htm
 

Ohr Pharmaceutical, Inc. 10-K

 

Exhibit 32.2 

Certification of Chief Financial Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

 

Not Filed Pursuant to the Securities Exchange Act of 1934

  

In connection with the Annual Report of Ohr Pharmaceutical, Inc. (the “Company”) on Form 10-K for the fiscal year ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sam Backenroth, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: December 15, 2017

 

/s/ Sam Backenroth  
Sam Backenroth, Chief Financial Officer  
(Principal Financial and Accounting Officer)

 

 

 

NeuBase Therapeutics, Inc. Reports